A Moll

Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

Multi-input chemical control of protein dimerization for programming graded cellular responses

Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir

Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS

COVID-19: A promising cure for the global panic

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa

Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel

Hepatitis C Virus: 30 Years after Its Discovery

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV

Antiretroviral Treatment of Adult HIV Infection

Taming a beast: lessons from the domestication of hepatitis C virus

Validating the vitality strategy for fighting drug resistance

Protease inhibitor therapy for hepatitis C virus-infection

Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States

UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone

Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

Considerable Under-Treatment of Chronic HCV Infection in HIV Patients despite Acceptable Sustained Virological Response Rates in a Real-Life Setting

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?